Double-Blind?

Baselineb and Change in PTSD Measure

Statistically Significant? (versus control)

Loss of Diagnosis or Clinical Improvement (%)

Principal Limitations

Yes

~59

 

N/A

Dropout data aggregated with 36% overall dropout; no handling of missing data

 

−4.4

No

 

 

−6.8

 

Yes

~35

 

N/A

Dropout data NR; completer analysis only

 

−3.8c

No

 

 

0.4

 

baseline data (before treatment began). Average baseline score when reported or when baseline scores for all arms are nearly the same; otherwise, baseline scores listed individually in order of arm.

cResults at 4 weeks.

(propranolol) began within 6 hours after the traumatic event so the subjects could not have been diagnosed with PTSD (Pitman et al., 2002). See Table 3-11 for a summary of the two included RCTs.

SUMMATION

Based on its assessment of the medications for which randomized controlled trials were available—alpha-adrenergic blockers, anticonvulsants, novel antipsychotic medications, benzodiazepines, MAOIs, SSRIs, and other antidepressants—the committee found the evidence for all classes of drugs reviewed inadequate to determine efficacy for patients with PTSD. Important comments are appended to the conclusions for alpha-adrenergic blockers, novel antipsychotics, benzodiazepines, and SSRIs.

REFERENCES

Ahearn, E. P., M. Mussey, C. Johnson, A. Krohn, and D. Krahn. 2006. Quetiapine as an adjunctive treatment for post-traumatic stress disorder: An 8-week open-label study. International Clinical Psychopharmacology 21(1):29-33.

APA (American Psychiatric Association). 2004. Practice guideline for the treatment of patients with acute stress disorder and posttraumatic stress disorder. Arlington, VA: APA.



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement